Verrica Pharmaceuticals (NASDAQ:VRCA) released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.30) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.02), Fidelity Earnings reports.
Shares of Verrica Pharmaceuticals stock opened at $7.99 on Friday. The company has a market cap of $205.41 million and a PE ratio of -5.67. Verrica Pharmaceuticals has a twelve month low of $6.44 and a twelve month high of $23.29.
In other news, major shareholder Matt Davidson sold 20,558 shares of the stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $11.72, for a total transaction of $240,939.76. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 190,850 shares of company stock worth $2,109,290 over the last quarter. Insiders own 40.20% of the company’s stock.
Several analysts have issued reports on VRCA shares. HC Wainwright started coverage on Verrica Pharmaceuticals in a research note on Thursday, February 21st. They set a “buy” rating and a $20.00 price objective on the stock. Zacks Investment Research cut Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 11th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Verrica Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $26.25.
Verrica Pharmaceuticals Company Profile
Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts.
Featured Story: What is the Consumer Price Index (CPI)?
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.